<DOC>
	<DOCNO>NCT01394562</DOCNO>
	<brief_summary>The purpose study confirm treatment IV ferric carboxymaltose improve exercise capacity , physical functioning quality life patient iron deficiency chronic heart failure .</brief_summary>
	<brief_title>Effect Ferric Carboxymaltose Exercise Capacity Patients With Iron Deficiency Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Iron deficient subject stable chronic heart failure ( CHF ) ( NYHA IIIII ) optimal background therapy CHF Reduced exercise capacity Reduced leave ventricular ejection fraction At least 18 year age write informed consent prior study specific procedure Erythropoietin stimulate agent ( ESA ) use , IV iron therapy , and/or blood transfusion previous 6 week prior randomisation Exercise training program ( ) 3 month prior screen plan next 6 month Chronic liver disease and/or elevate liver enzymes Vitamin B12 and/or serum folate deficiency Subject use adequate contraceptive precaution study No significant cardiac general disorder would compromise participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>